EXHIBIT A JOINT FILING AGREEMENT JOINT FILING AGREEMENT, dated as of November 24, 2008, among INVUS PUBLIC EQUITIES, L.P., INVUS PUBLIC EQUITIES ADVISORS, LLC, ULYS, L.L.C., and RAYMOND DEBBANE (collectively, the "Joint Filers"). WHEREAS, pursuant to...Joint Filing Agreement • November 25th, 2008 • Invus Public Equities, LP • Pharmaceutical preparations
AMENDED AND RESTATED JOINT FILING AGREEMENTJoint Filing Agreement • April 10th, 2012 • Invus Public Equities, LP • Pharmaceutical preparations
This Amended and Restated Joint Filing Agreement (this “Agreement”) amends and restates the Joint Filing Agreement, dated February 14, 2012, by and among Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Ulys, L.L.C. and Raymond Debbane.
EXHIBIT BStockholder Agreement • November 25th, 2008 • Invus Public Equities, LP • Pharmaceutical preparations • Delaware
JOINT FILING AGREEMENTJoint Filing Agreement • February 16th, 2021 • Invus Public Equities, L.P. • Biological products, (no disgnostic substances)
The undersigned agree that the statement on Schedule 13G with respect to the common stock, $0.001 par value per share, of SQZ Biotechnologies Company, dated as of February 12, 2021, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2019 • Invus Public Equities, L.P. • Pharmaceutical preparations
The undersigned agree that the statement on Schedule 13G/A with respect to the common stock, $0.001 par value per share, of ProQR Therapeutics N.V., dated as of February 12, 2019, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • November 13th, 2020 • Invus Public Equities, L.P. • Biological products, (no disgnostic substances)
The undersigned agree that the statement on Schedule 13G with respect to the common stock, $0.001 par value per share, of SQZ Biotechnologies Company, dated as of November 13, 2020, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • May 26th, 2006 • Invus Public Equities, LP • Pharmaceutical preparations
JOINT FILING AGREEMENT, dated as of the 26th day of May, 2006, among INVUS PUBLIC EQUITIES, L.P., INVUS PUBLIC EQUITIES ADVISORS, LLC, ULYS, LLC, AND RAYMOND DEBBANE (COLLECTIVELY, THE “JOINT FILERS”).
